Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies
Pharmaceutical Investing Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
